Fine specificity analysis of an HLA-A2.1-restricted immunodominant T cell epitope derived from human α-fetoprotein

Molecular Immunology

Volumn 37, Issue 16, 2000, Pages 943-950

  Meng, Wilson S ^a   Butterfield, Lisa H ^a   Ribas, Antoni ^a,b   Heller, Justin B ^a   Dissette, Vivian B ^a   Glaspy, John A ^b   McBride, William H ^b   Economou, James S ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antigenic peptides; Hepatocellular carcinoma; HLA A2.1; Fetoprotein

Indexed keywords

ALANINE; ALPHA FETOPROTEIN; EPITOPE; GLUTAMINE; HLA A2 ANTIGEN; LEUCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL SPECIFICITY; CONTROLLED STUDY; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNIZATION; MOLECULAR MODEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE;

EID: 0034993982     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-5890(01)00017-7     Document Type: Article

References (37)

1. Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line
2. Serum α-fetoprotein in a mouse strain (C3H-Avy fB) with spontaneous hepatocellular carcinomas
3. The density of peptides displayed by dendritic cells affects immune responses to human tyrosinase and gp100 in HLA-A2 transgenic mice
4. Generation of human T cell responses to an HLA-A2.1-restricted peptide epitope from α-fetoprotein
5. T cell responses to HLA-A*0201-restricted peptides derived from α-fetoprotein
6. Naive versus memory CD4 T cell response to antigen: Memory cells are less dependent on accessory cell costimulation and can respond to many antigen-presenting cell types including resting B cells
7. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules
8. Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors
9. Structural basis of plasticity in T cell receptor recognition of a self peptide-MHC antigen
10. Structural basis of T cell recognition
11. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor
12. Species-restricted interactions between CD8 and the α-3 domain of class I influence the magnitude of the xenogeneic response
13. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes
14. The importance of pairwise interactions between peptide residues in the delineation of TCR specificity
15. Cell-ELISA using β-galactosidase conjugated antibodies
16. The antigenic identity of peptide-MHC complexes: A comparison of the conformations of five viral peptides presented by HLA-A2
17. Differential recognition of peptide analogs by naive verses activated PLP 139-151-specific CD4+ T cells
18. A model of water structure inside the HLA-A2 peptide binding groove
19. Modeling of the non-obese diabetic mouse class II MHC molecule I-Ag7
20. Water dynamics at the binding interface of four different HLA-A2-peptide complexes
21. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
22. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains
23. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues
24. Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells
25. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma
26. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
27. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules
28. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes
29. Selecting T cell receptors with high affinity for self-MHC by decreasing the contribution of CD8
30. Identification of T-cell epitopes: Rapid isolation of class I-presented peptides from viable cells by mild acid elution
31. Targeting p53 as a general tumor antigen
32. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/Mart-1 immunodominant peptide analogues
33. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatability complex
34. Alpha fetoprotein-specific immunotherapy for hepatocellular carcinoma
35. Differences and similarities in the A2.1-restricted cytotoxic T cell repertoire in humans and human leukocyte antigen-transgenic mice